Tresiba ® is really a once-daily, lengthy-acting insulin indicated to enhance glycemic control in patients 12 months old and older with diabetes. 1 See details below.

Tresiba ® FlexTouch ® is available in 2 dose formulations: U-200 and U-100. 1

Tresiba ® FlexTouch ® U‑100

Concentration

100 units/mL

Pens per package

Volume per pen

Units of insulin per pen

Units of insulin per package

1500 units

Max dose per injection

Dose increments

NDC number

0169-2660-15

Tresiba ® FlexTouch ® U‑200

Concentration

200 units/mL

Pens per package

Volume per pen

Units of insulin per pen

Units of insulin per package

1800 units

Max dose per injection

Dose increments

NDC number

0169-2550-13

Other details about Tresiba ® 1 :

Injected subcutaneously once daily, as well as for adults, anytime of day

• Instruct adult patients who miss a serving of Tresiba ® to inject their daily dose during waking hrs upon finding the missed dose, then continue your regular dosing schedule
• Tresiba ® should be dosed simultaneously every day for pediatric patients. Instruct pediatric patients who miss a serving of Tresiba ® to make contact with their doctor for guidance and also to monitor bloodstream blood sugar levels more often before the next scheduled dose
• Instruct adult patients to make sure that a minimum of 8 hrs have passed between consecutive Tresiba ® injections

The suggested time between dose increases is three or four days

• No dose conversion needed

• Opened up (in-use) Tresiba ® could be stored at 70 degrees (below 86°F), from direct heat and lightweight, or refrigerated (36°F to 46°F) for 56 days (8 days)

Qualified patients pay less than $15 per 30-day give you a

a For approximately 24 several weeks. Maximum savings of $500 per prescription. Eligibility along with other limitations apply.

Remember to buy
NovoFine ® Plus disposable needles

The 32G, 4 mm pen needle is Novo Nordisk’s shortest and thinnest needle available. b

Provide your patients a game title plan using the Diabetes Health Coach

Live calls from the Certified Diabetes Educator for that first 3 months of therapy for patients with diabetes beginning Tresiba ® , obtainable in both British and Spanish. c

Personalized online coaching sessions on greater than 25 topics—developed by leading diabetes experts.

Ongoing support which includes tools, education, interactive trackers, and diabetes-friendly recipes.

Encourage patients taking Tresiba ® to join up for personalized support.

b Needles are offered individually and could need a prescription in certain states.

c Patients with diabetes be eligible for a live phone support should they have been taking Tresiba ® for under 6 several weeks and requested calls when subscribing to Cornerstones4Care ® .

Qualified patients will pay less than $15 for any 30-day way to obtain Tresiba ®d

d For approximately 24 several weeks. Maximum savings of $500 per prescription. Eligibility along with other limitations apply.

Selected Important Safety Information

Contraindications

• Tresiba ® is contraindicated during instances of hypoglycemia as well as in patients with hypersensitivity to Tresiba ® a treadmill of their excipients

Warnings and Safeguards

• Never Share a Tresiba ® FlexTouch ® Pen Between Patients, whether or not the needle is altered. Discussing poses a danger for transmission of bloodstream-borne pathogens
• Monitor bloodstream glucose in most patients given insulin. Alterations in insulin may affect glycemic control. These changes ought to be made very carefully and under medical supervision. Adjustments in concomitant anti-diabetic treatment may be required
• Hypoglycemia is easily the most common adverse result of insulin, including Tresiba ® , and could be existence-threatening

Indications and Usage

Tresiba ® (insulin degludec injection) is indicated to enhance glycemic control in patients 12 months old and older with diabetes.

Limitations useful

Tresiba ® isn’t suggested for the treatment of diabetic ketoacidosis or pediatric patients requiring under 5 units of Tresiba ® .

Important Safety Information

Contraindications

• Tresiba ® is contraindicated during instances of hypoglycemia as well as in patients with hypersensitivity to Tresiba ® a treadmill of their excipients

Warnings and Safeguards

• Never Share a Tresiba ® FlexTouch ® Pen Between Patients, whether or not the needle is altered. Discussing poses a danger for transmission of bloodstream-borne pathogens
• Monitor bloodstream glucose in most patients given insulin. Alterations in insulin may affect glycemic control. These changes ought to be made very carefully and under medical supervision. Adjustments in concomitant anti-diabetic treatment may be required
• Hypoglycemia is easily the most common adverse result of insulin, including Tresiba ® , and could be existence-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, exercise as well as in patients with hypoglycemia unawareness or kidney or hepatic impairment
• Accidental mix-ups between basal insulin products along with other insulins, particularly rapid-acting insulins, happen to be reported. To prevent medication errors, always instruct patients to determine the insulin label before each injection
• Severe, existence-threatening, generalized allergy, including anaphylaxis, can happen with insulin products, including Tresiba ®
• As with every insulins, Tresiba ® use can result in existence-threatening hypokalemia, which in turn could cause respiratory system paralysis, ventricular arrhythmia, and dying. Carefully monitor potassium levels in patients vulnerable to hypokalemia and treat if indicated
• Fluid retention and heart failure can happen with concomitant utilization of thiazolidinediones (TZDs), that are PPAR-gamma agonists, and insulin, including Tresiba ® . Patients ought to be observed for signs and signs and symptoms of heart failure. If heart failure occurs, dosage reduction or stopping from the TZD should be considered

Side Effects

• Side effects generally connected with Tresiba ® are hypoglycemia, allergy symptoms, injection site reactions, lipodystrophy, pruritus, rash, edema, and putting on weight

Drug Interactions

• There are specific drugs that could cause clinically significant drug interactions with Tresiba ® .

• Drugs that could raise the chance of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
• Drugs that could reduce the bloodstream glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, dental contraceptives, phenothiazines, progestogens (e.g., in dental contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
• Drugs that could decrease or increase the bloodstream glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
• Drugs that could blunt the twelve signs and signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine

Please get more information at Prescribing Information.

1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Corporation August 2018.

Cornerstones4Care ® , FlexTouch ® , Levemir ® , NovoFine ® , NovoLog ® , Tresiba ® , and Victoza ® are registered trademarks and NovoMedLink™ is really a trademark of Novo Nordisk A/S.

Novo Nordisk is really a registered trademark of Novo Nordisk A/S.

Other trademarks, registered or unregistered, belong to their particular proprietors.

Source: www.tresibapro.com

Tresiba® FlexTouch® (insulin degludec injection) 100 U/mL: How to use